Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 793 | 0.82 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 12034
Sealed predictions
- IFITM3 in dopamine neurons, braak-0.83 (p 0.005) → -0.15 (p 0.697)receipt 12040
Swarm cases
receipt 12040: IFITM3 in dopamine neurons, braak
- power
- full sample -0.50 (p 0.033, n 18), 95% CI -0.79 to -0.05. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.50 (p 0.033, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.057, n 18). could be the mix.
- skeptic
- leave-one-out range -0.62 to -0.44, sign flips 0; without severely affected donors -0.50 (p 0.033, n 18). robust.
- cell type
- strongest in astrocytes: -0.64 (p 0.0040, n 18) vs -0.50 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IFITM3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up IFITM3 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.65 p 0.021 (needs p < 1.8e-4)
Receipts
loading the receipts